Cognitive Dysfunction And Dementia In Parkinson’s Disease
J. Bosboom, D. Stoffers, E. C. Wolters
Published 2004 · Psychology, Medicine
Download PDFAnalyze on Scholarcy
Summary.Parkinson’s disease (PD) is a slowly progressive neurodegenerative disorder mainly characterized by degeneration of dopaminergic neurons in the substantia nigra and the ventral tegmental area, in combination with a varying loss of central noradrenergic (locus coeruleus), cholinergic (nucleus basalis of Meynert) and serotonergic (dorsal raphe nuclei) integrity, leading to a multitude of motor and non-motor behavioral disturbances.Apart from the clinical motor hallmarks, in the early stages of disease, subtle cognitive dysfunction might be seen comprising mainly executive dysfunction, with secondary visuospatial and mnemonic disturbances. In about 20–40% of patients, these problems may eventually proceed to dementia, which constitutes an important risk factor for caregiver distress, decreased quality of life and nursing home placement. Dementia in PD is typically characterized by a progressive dysexecutive syndrome with attentional deficits and fluctuating cognition, often accompanied by psychotic symptoms. It is thought to be the result of a combination of both subcortical and cortical changes. PD-related dopaminergic deficiency in the nucleus caudatus and mesocortical areas (due to degeneration of projections from the substantia nigra and ventral tegmental area) and cholinergic deficiency in the cortex (due to degeneration of ascending projections from the nucleus basalis of Meynert), combined with additional Alzheimer-pathology and cortical Lewy bodies, may greatly contribute to dementia.Current treatment of dementia in PD is based on compensation of the profound cholinergic deficiency. Recent studies with the cholinesterase inhibitors galantamine, donepezil and rivastigmine show promising results in improving cognition and ameliorating psychotic symptoms, which must further be confirmed in randomized controlled trials.
This paper references
The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia
E. A. Werber (2001)
Studies on mesocortical dopamine systems.
A. M. Thierry (1978)
Contributions of Frontal System Dysfunction to Memory and Perceptual Abilities in Parkinson's Disease
Mark W. Bondi (1993)
Memory and learning in early Parkinson's disease: Evidence for a “frontal lobe syndrome”
A. Taylor (1990)
Visuospatial memory deficits at different stages of Parkinson's disease
A. Owen (1993)
Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: A cross-sectional comparative study.
David J. Burn (2003)
Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients.
J. Kulisevsky (2000)
Is impaired memory for spatial location in Parkinson's disease domain specific or dependent on ‘strategic’ processes?
Bernard Pillon (1998)
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study.
Irene Litvan (1998)
Clinical and biochemical correlates of bradyphrenia in Parkinson's disease
R. Mayeux (1987)
Dopaminergic effects on cognitive performance in patients with Parkinson's disease.
K. Lange (1995)
Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression.
V. Chan-Palay (1989)
Rivastigmine for the Treatment of Dementia and Visual Hallucinations Associated with Parkinson's Disease: A Case Series
R. Bullock (2002)
Psychosis in Parkinson's disease.
Werner Poewe (2003)
Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response.
H. Apaydin (2002)
Antecedent clinical features associated with dementia in Parkinson's disease
Yaakov Stern (1993)
Mental symptoms in Parkinson's disease are important contributors to caregiver distress.
D. Aarsland (1999)
Delusions associated with elevated muscarinic binding in dementia with Lewy bodies.
Clive G Ballard (2000)
Visuospatial impairment in Parkinson's disease. Role of perceptual and motor factors.
F. Boller (1984)
Role of Dopamine in Learning and Memory
Jaime Kulisevsky (2000)
A 5-month, randomized, placebo-controlled trial of galantamine in AD
P. Tariot (2000)
Acute and Long-Term Administration of Anticholinergics in Parkinson's Disease: Specific Effects on the Subcortico-Frontal Syndrome
M. Bédard (1999)
Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease.
S. Woods (2003)
Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.
D. Aarsland (2000)
Encoding Deficits in Untreated Parkinson's Disease
James A. Cooper (1993)
Basal forebrain neurons in the dementia of Parkinson disease.
P. Whitehouse (1983)
Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.
P J Reading (2001)
Psychiatric complications in the treatment of Parkinson's disease.
Erik Ch. Wolters (2001)
Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer disease.
D. Connor (1998)
Successful Use of Donepezil for the Treatment of Psychotic Symptoms in Patients With Parkinson's Disease
Joseph A. Bergman (2002)
Motor impairment in PD
Gilberto Levy (2000)
Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases.
B. Pillon (1993)
Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow.
A. Taylor (1986)
Dementia and cognitive impairment in Parkinson's disease.
Floriano Girotti (1988)
Rivastigmine (Exelon) for dementia in patients with Parkinson's disease.
Nir Giladi (2003)
Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity
R. Oades (1987)
Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease
P. Mattila (2000)
Dementia in idiopathic Parkinson's disease
Teresita S. Elizan (1986)
Neuropsychological differences between the dementias of Alzheimer's and Parkinson's diseases.
S. Huber (1989)
Ventral segmental (A10) system: neurobiology
RD Oades (1987)
Psychosis in Parkinson's disease Visuoperception and visuospatial and visuorotational performance in Parkinson's disease
W Poewe (1987)
Convergent cholinergic activities in aging and Alzheimer's disease
E. Perry (1992)
Memory and learning strategies in patients with Parkinson's disease
Elly L. Buytenhuijs (1994)
Choline acetyltransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment
P. Mattila (2001)
Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.
D. Aarsland (2003)
Cognitive Deficits in Parkinson’s Disease
A. Lees (1985)
Mental dysfunctions in Parkinson ’ s disease
EC Wolters (1998)
Parkinson's disease and dementia
R. Cash (1987)
Memory and executive function impairment predict dementia in Parkinson's disease.
G. Levy (2002)
In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease.
D. Kuhl (1996)
Confusion, dementia and anticholinergics in Parkinson's disease.
Y de Smet (1982)
Neuropsychological characteristics of preclinical dementia in Parkinson's disease
D. M. Jacobs (1995)
Dementia in Parkinon’s disease: subclinical Alzheimer’s disease? In: Wolters ECh, Scheltens Ph, Berendse HW (eds) Mental dysfunctions in Parkinson’s disease
Scheltens Ph (1999)
Dementia in Parkinon's disease: subclinical Alzheimer's disease? In: Wolters ECh, Scheltens Ph, Berendse HW (eds) Mental dysfunctions in Parkinson's disease II
Scheltens Ph (1999)
Cholinesterase inhibition in Parkinson's disease.
Michael Hutchinson (1996)
Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial.
J B Grace (2001)
Dissociating executive mechanisms of task control following frontal lobe damage and Parkinson's disease.
R. Rogers (1998)
The cholinergic hypothesis of Alzheimer’s disease: a review of progress
T. Babić (1999)
Cortical Lewy body pathology in the diagnosis of dementia
A. Harding (2001)
Parkinsonism: Effects of levodopa treatment on concept formation
Florry Proctor Bowen (1975)
Storage and executive processes in the frontal lobes.
E. Smith (1999)
The Neuropathologic Basis of Different Clinical Subgroups of Parkinson's Disease
W. Paulus (1991)
Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial.
Ian G. McKeith (2000)
Dementia in Parkinson’s disease: incidence and associated factors at 14-years of follow-up
NL Read (2001)
Neuropsychological prediction of dementia in Parkinson’s disease
T. Hughes (1998)
Attention to action in Parkinson's disease: impaired effective connectivity among frontal cortical regions.
J. Rowe (2002)
Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?
B. Pillon (1989)
Neuropathological correlates of mental dysfunction in Parkinson’s disease: an update
KA Jellinger (1999)
Dementia in Parkinon ’ s disease : subclinical Alzheimer ’ s disease ?
Scheltens Ph (1999)
Parkinson’s disease and dementia: norepinephrine and dopamine in locus
R Cash (1987)
Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia.
I. McKeith (2000)
Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease.
E. Perry (1991)
Risk of dementia in Parkinson’s disease
D. Aarsland (2001)
Frontal lobe dysfunction in Parkinson's disease: prognostic value for dementia?
M. Piccirilli (1989)
Frontal-subcortical circuits and human behavior.
J. Cummings (1993)
Cognitive deficits and dementia in Parkinson's disease Aging and dementia
B Pillon (2001)
Striatal contributions to working memory: a functional magnetic resonance imaging study in humans.
S. Lewis (2004)
Visuospatial working memory in Parkinson's disease.
V. A. Bradley (1989)
Cognitive speed in nondemented Parkinson's disease.
M. C. Smith (1998)
Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease
K. Jellinger (2002)
Slowed central processing in simple and go/no-go reaction time tasks in Parkinson's disease.
J. Cooper (1994)
Cholinergic dysfunction in diseases with Lewy bodies
P. Tiraboschi (2000)
Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.
D. Aarsland (2003)
Frequency of dementia in Parkinson disease.
Dag Aarsland (1996)
l-Dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction
K. Lange (2005)
Friedhoff LT (1998b) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease
SL Rogers (1998)
Lewy body, neurofibrillary tangle and senile plaque pathology in Parkinson’s disease patients with and without dementia
K SantaCruz (1999)
Parallel organization of functionally segregated circuits linking basal ganglia and cortex.
G. E. Alexander (1986)
Fluctuations in attention
C. Ballard (2002)
An estimate of the incidence of dementia in idiopathic Parkinson??s disease
R. Mayeux (1991)
Parkinson's disease and dementia with Lewy bodies: one disease or two?
I. Richard (2002)
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study
D. Aarsland (2002)
Psychotic symptoms in Parkinson's disease: pathophysiology and management.
Johannes L. Bosboom (2004)
Performance on the dementia rating scale in Parkinson’s disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer’s disease
D. Aarsland (2003)
'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa.
A. M. Gotham (1988)
Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra.
J. Rinne (1989)
Visuoperception and visuospatial and visuorotational performance in Parkinson's disease
Gerhard Ransmayr (1987)
Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR.
M. Samochocki (2000)
Spatial and non-spatial working memory at different stages of Parkinson's disease
A. Owen (1997)
Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.
G. Fénelon (2000)
Parkinsonism: alterations in spatial orientation as determined by a route-walking test.
F. P. Bowen (1972)
Set-shifting and spatial orientation in patients with Parkinson's disease.
Sarah A. Raskin (1992)
Abnormal basal ganglia outflow in Parkinson's disease identified with PET. Implications for higher cortical functions.
A. Owen (1998)
Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease
G. Fabbrini (2002)
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.
Ian G. McKeith (1996)
Cholinergic Transmitter and Neurotrophic Activities in Lewy Body Dementia: Similarity to Parkinson's and Distinction from Alzheimer Disease
E. Perry (1993)
Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson’s disease
P. Mattila (1998)
Visuospatial function in Parkinson's disease.
R. Brown (1986)
The frequency and associated risk factors for dementia in patients with Parkinson's disease.
K. Marder (1995)
Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.
E. Perry (1985)
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
P. Davies (1976)
Deficits on visuospatial tests involving forward planning in high-functioning Parkinsonians
JA Ogden (1990)
Neuropathological correlates of mental dysfunction in Parkinson's disease: an update. In: Wolters ECh, Scheltens Ph, Berendse HW (eds) Mental dysfunctions in Parkinson's disease II
Ka Jellinger (1999)
A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease
T. Hughes (2000)
High Speed Memory Scanning in Parkinsonism
R. Wilson (1980)
Metrifonate treatment of the cognitive deficits of Alzheimer's disease
Jeffrey L. Cummings (1998)
Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease.
D. Burn (2003)
A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender.
Richard P. Mayeux (1992)
Cognitive deficits and structural brain changes associated with dementia and visual hallucinations in Parkinson's disease
Blanca Ruiz (2006)
Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions
Carlo Gabelli (2003)
Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients.
J. Cooper (1992)
Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease
B. Scatton (1983)
An estimate of the prevalence of dementia in idiopathic Parkinson's disease.
R. Mayeux (1988)
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
S. L. Rogers (1998)
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study
I. Mckeith (2000)
Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey.
M. Mesulam (1983)
‘Lewy body disease’: clinico-pathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia
Rob Ai De Vos (1995)
Spatial disorientation as an early symptom of Parkinson's disease
A. Hovestadt (1987)
Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease
H. Hurtig (2000)
Cholinergic dysfunction in diseases
P Tiraboschi (2000)
Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Ch1–Ch6)
M. Mesulam (1983)
This paper is referenced by
Brain Imaging in Behavioral Neuroscience
Cameron S. Carter (2012)
Intra-individual reaction time variability in sustained attention
Rachel Ann Moss (2018)
Deep brain stimulation state of the art and novel stimulation targets.
Francisco A. Ponce (2010)
Leichte kognitive Störungen und Demenz bei Patienten mit Morbus Parkinson
Elke Kalbe (2014)
Computer aided analysis of cognitive disorder in patients with Parkinsonism using machine learning method with multilevel ROI-based features
Bo Peng (2016)
Cognitive Profiles in Parkinson's Disease and Their Relation to Dementia: A Data-Driven Approach
Inga Liepelt-Scarfone (2012)
BINDING TO CORTICAL MUSCARINIC RECEPTORS IN UNILATERALLY 6-HYDROXYDOPAMINE LESIONED RATS
Remco J. J. Knol (2008)
The effects of cognitive behavioral and mindfulness-based therapies on psychological distress in patients with multiple sclerosis, Parkinson's disease and Huntington's disease: Two meta-analyses.
Ires Ghielen (2019)
Lack of long-term changes in circadian, locomotor, and cognitive functions in acute and chronic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse models of parkinson’s disease
Karim Fifel (2013)
The organization of narrative discourse in Lewy body spectrum disorder
Sharon Ash (2011)
Heterogeneous Distribution of Kir3 Potassium Channel Proteins Within Dopaminergic Neurons in the Mesencephalon of the Rat Brain
D. Eulitz (2006)
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease.
M Horstink (2006)
Pathophysiology of Non-Dopaminergic Monoamine Systems in Parkinson's Disease: Implications for Mood Dysfunction
Nirmal Bhide (2011)
Functional Imaging of Cognitive Impairment in Parkinson's Disease
Toni Fitzpatrick (2010)
Intranasal Administration of Neurotoxicants in Animals: Support for the Olfactory Vector Hypothesis of Parkinson’s Disease
R. Prediger (2011)
Autonomic dysfunction is associated with neuropsychological impairment in Lewy body disease
Rocío Del Pino (2020)
Virtual multiple errands test (VMET): a virtual reality-based tool to detect early executive functions deficit in Parkinson’s disease
Pietro Cipresso (2014)
Exploring Virtual Reality for the Assessment and Rehabilitation of Executive Functions
Elisa Pedroli (2018)
Dementia and mild cognitive impairment in patients with Parkinson's disease.
Hélio Afonso Ghizoni Teive (2009)
Conceptual Hypometria? An evaluation of conceptual mapping of space in Parkinson's disease
F. M. Skidmore (2009)
Long-Lasting Paracrine Effects of Human Cord Blood Cells on Damaged Neocortex in an Animal Model of Cerebral Palsy
Sang-Hun Bae (2012)
The endogenous repair capacity of the parkinsonian brain
Simone A. van den Berge (2011)
A process-model based approach to prospective memory impairment in Parkinson's disease
Matthias Kliegel (2011)
Assoziationen zwischen bildgebenden, kognitiven und motorischen Testverfahren zur Früherkennung des
Ärztlicher Direktor (2012)
Cholinergic systems in progressive supranuclear palsy.
N. Warren (2005)
Persian version of frontal assessment battery: Correlations with formal measures of executive functioning and providing normative data for Persian population
S. Asaadi (2016)
Problem solving therapy for the treatment of depression for a patient with Parkinson’s disease and mild cognitive impairment: a case study
R Scott Mackin (2006)
Application of Machine Learning Technique to Distinguish Parkinson’s Disease Dementia and Alzheimer’s Dementia: Predictive Power of Parkinson’s Disease-Related Non-Motor Symptoms and Neuropsychological Profile
Haewon Byeon (2020)
KÄELISTE OSKUSTE HINDAMINE ALZHEIMERI TÕVEGA JA PARKINSONI TÕVEST TINGITUD DEMENTSUSEGA PATSIENTIDEL Magistritöö
E. Tamme (2013)
Novelty processing and memory formation in Parkinson׳s disease
Judith Schomaker (2014)
Donepezil and α-synuclein Constipation: A 36 Month Follow-Up
Charles M. Lepkowsky (2019)
Adherence therapy for people with Parkinson's disease
David James Daley (2013)See more